Pro Re Nata Intravitreal Bevacizumab for the Treatment of Idiopathic Choroidal Neovascular Membrane

Saurabh, Kumar; Roy, Rupak; Panigrahi, Pradeep Kumar; Lobo, Aneesha; Majumdar, Anindya Kishore

doi:10.3109/08820538.2014.962172

Cited by 4 publications

(6 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anti-VEGF therapy used at baseline and then PRN has been found comparable efficacy in most of the studies on ICNV [7,9,17,18]. Previous studies [7,15] have found that intravitreal bevacizumab on a PRN basis was effective in the treatment of ICNV and suggested that a single loading injection, followed by as-needed dosing, achieved favorable outcome. Taking Chinese current medical environment into account, we thought that the 1 + PRN regimen not only reduced the burden of patients' costs, but also reduced the risk of systemic complications caused by repeated intravitreal injections [19].…”

Section: Discussionmentioning

confidence: 96%

“…After one intravitreal ranibizumab (IVR, 1.25 mg/0.05 ml, Novartis, Schweiz) or bevacizumab (IVB, 1.25 mg/0.05 ml, Genentech, USA) injection, patients were assessed monthly and received pro re nata (PRN) treatments until there was no sign of CNV activity based on the following criteria: no presence of subretinal/intraretinal fluid, no persistent/recurrent retinal haemorrhage or no drop in visual acuity of 5 letters, or the lesion became compact and only cicatricial CNV remained compared to the previous visits on OCT [14,15]. Either bevacizumab or ranibizumab was used as monotherapy.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of efficacy and recurrence for anti-vascular endothelial growth factor therapy in idiopathic choroidal neovascularization

Feng

Liu

et al. 2020

BMC Ophthalmol

View full text Add to dashboard Cite

Background: This study aimed to evaluate the visual and morphological outcomes of intravitreal anti-VEGF therapy and the recurrence for idiopathic choroidal neovascularization (ICNV). Methods: This retrospective study included 35 patients (35 eyes) with ICNV from July 2012 to October 2017. All patients received 1 intravitreal anti-VEGF injection followed by pro re nata injections until there was no sign of ICNV activity. This was defined as the first follow-up period. To evaluate ICNV recurrence, we continued to follow-up 27 of the 35 patients for at least 2 years after the initial diagnosis, and the longest follow-up period was 5 years. Additional injection was performed when ICNV recurred. Best corrected visual acuity (BCVA) and central retinal thickness (CRT) were recorded and morphological improvement in optical coherence tomography (OCT) was assessed. Parameters that affect prognosis and recurrence were analysed.Results: The mean follow-up period was 168.0 ± 34.82 weeks. Mean BCVA improved from 56.20 ± 14.13 letters at baseline to 73.31 ± 12.57 letters (P<0.01); Mean CRT decreased from 353.6 ± 98.70 μm at baseline to 273.1 ± 53.56 μm (P < 0.001) at the end of the first follow-up period. Better baseline BCVA indicated a better morphological improvement (P = 0.026) in OCT: the lesion had completely subsided with recovery of the foveal contour. Those with high baseline BCVA (more than 60 letters) showed significant resolution of CNV lesions (P = 0.036). ICNV recurred in six patients (22.2%), 1 of whom experienced 2 recurrences. The mean timing of recurrence was 90.83 ± 49.02 weeks after diagnosis. There was no significant correlation between ICNV recurrence and the morphological improvement (P = 0.633). The final BCVA in patients with recurrence did not differ from that in patients without recurrence (P = 0.065).

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Methodsmentioning

confidence: 99%

Evaluation of efficacy and recurrence for anti-vascular endothelial growth factor therapy in idiopathic choroidal neovascularization

Feng

Liu

et al. 2020

BMC Ophthalmol

View full text Add to dashboard Cite

show abstract

“…Unlike AMD, CNV lesions are smaller in patients with ICNV than in patients with AMD, with the former characterized by mild edema and less bleeding. Patients with ICNV are usually treated using the 1 + PRN treatment plan [ 24 – 26 ]. Conbercept, a recombinant fusion protein, can block the binding of VEGF to its receptor and inhibit the formation of CNV.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of intravitreal injections of conbercept for the treatment of idiopathic choroidal neovascularization

Zhai,

Su,

Wang

et al. 2024

BMC Ophthalmol

View full text Add to dashboard Cite

Background To determine the efficacy and safety of intravitreally injected conbercept, a vascular endothelial growth factor receptor fusion protein, for the treatment of idiopathic choroidal neovascularization (ICNV). Methods This retrospective study analyzed outcomes in 40 patients (40 eyes) with ICNV who received intravitreal injections of conbercept 0.5 mg (0.05 ml) and were followed up for at least 12 months. All patients underwent full ophthalmic examinations, including best-corrected vision acuity (BCVA), intraocular pressure (IOP), slit-lamp examination, color fundus photography, optical coherence tomography angiography, multifocal electroretinogram, and fundus fluorescence angiography, if necessary, at baseline and after 1, 3, 6, and 12 months. BCVA, macular central retinal thickness (CRT), IOP, CNV blood flow area, thickness of the CNV-pigment epithelial detachment complex, thickness of the retinal nerve fiber layer (RNFL), and the first positive peak (P1) amplitude density in ring 1 before and after treatment were compared. Results Mean baseline BCVA (logMAR), CRT, CNV blood flow area, and CNV-pigment epithelial detachment complex thickness were significantly lower 1, 3, 6, and 12 months after than before conbercept treatment (P < 0.05 each). IOP and baseline RNFL thickness were unaffected by conbercept treatment. P1 amplitude density was significantly higher 1, 3, 6, and 12 months after than before conbercept treatment (P < 0.05 each). None of the 40 eyes showed obvious ocular adverse reactions, such as endophthalmitis, glaucoma, cataract progression, and retinal detachment, and none of the patients experienced systemic adverse events, such as cardiovascular and cerebrovascular accidents. Conclusions Intravitreal injection of conbercept is beneficial to eyes with ICNV, inducing the recovery of macular structure and function and improving BCVA, while not damaging the neuroretina. Intravitreal conbercept is safe and effective for the treatment of ICNV.

show abstract

“…After one intravitreal ranibizumab (IVR, 1.25 mg/0.05ml, Novartis, Schweiz) or bevacizumab (IVB, 1.25 mg/0.05ml, Genentech, USA) injection, patients were assessed monthly and received pro re nata (PRN) treatments until there was no sign of CNV activity based on the following criteria: no presence of subretinal/intraretinal fluid, no persistent/recurrent retinal haemorrhage or no drop in visual acuity of 5 letters, or the lesion became compact and only cicatricial CNV remained compared to the previous visits on OCT (14,15). Either bevacizumab or ranibizumab was used as monotherapy.…”

Section: Methodsmentioning

confidence: 99%

“…Anti-VEGF therapy used at baseline and then PRN has been found comparable efficacy in most of the studies on ICNV (7,9,17,18). Previous studies (7,15) have found that intravitreal bevacizumab on a PRN basis was effective in the treatment of ICNV and suggested that a single loading injection, followed by as-needed dosing, achieved favorable outcome. Taking…”

Section: Comparison Between Subgroups According To Baseline Bcvamentioning

confidence: 96%

Evaluation of efficacy and recurrence for anti-vascular endothelial growth factor therapy in idiopathic choroidal neovascularization

Feng

Liu

et al. 2020

Preprint

View full text Add to dashboard Cite

Background This study aimed to evaluate the visual and morphological outcomes of intravitreal anti-VEGF therapy and the recurrence for idiopathic choroidal neovascularization (ICNV). Methods This retrospective study included 35 patients (35 eyes) with ICNV from July 2012 to October 2017. All patients received 1 intravitreal anti-VEGF injection followed by pro re nata injections until there was no sign of ICNV activity. This was defined as the first follow-up period. To evaluate ICNV recurrence, we continued to follow-up 27 of the 35 patients for at least 2 years after the initial diagnosis, and the longest follow-up period was 5 years. Additional injection was performed when ICNV recurred. Best corrected visual acuity (BCVA) and central retinal thickness (CRT) were recorded and morphological improvement in optical coherence tomography (OCT) was assessed. Parameters that affect prognosis and recurrence were analysed. Results The mean follow-up period was 168.0 ± 34.82 weeks. Mean BCVA improved from 56.20 ± 14.13 letters at baseline to 73.31 ± 12.57 letters (P＜0.01); Mean CRT decreased from 353.6 ± 98.70 μm at baseline to 273.1 ± 53.56 μm (P < 0.001) at the end of the first follow-up period. Better baseline BCVA indicated a better morphological improvement(P = 0.026) in OCT: the lesion had completely subsided with recovery of the foveal contour. Those with high baseline BCVA (more than 60 letters) showed significant resolution of CNV lesions (P = 0.036). ICNV recurred in six patients (22.2%), 1 of whom experienced 2 recurrences. The mean timing of recurrence was 90.83± 49.02 weeks after diagnosis. There was no significant correlation between ICNV recurrence and the morphological improvement (P = 0.633). The final BCVA in patients with recurrence did not differ from that in patients without recurrence (P=0.065). Conclusions Intravitreal anti-VEGF therapy on a pro re nata basis was effective for treating ICNV. High baseline BCVA indicated a better prognosis. Re-treatment with anti-VEGF could effectively lead to resolution of recurrent ICNV. Disease recurrence had no significant effect on final visual prognosis and had no correlation with the morphological improvement during treatment, suggesting that follow-up for subsequent monitoring should be performed in all ICNV patients.

show abstract

Pro Re Nata Intravitreal Bevacizumab for the Treatment of Idiopathic Choroidal Neovascular Membrane

Abstract: Intravitreal bevacizumab on a pro re nata basis is effective in the treatment of idiopathic choroidal neovascular membrane. A larger controlled study would be required to formulate an accurate injection protocol.

Cited by 4 publications

References 21 publications

Evaluation of efficacy and recurrence for anti-vascular endothelial growth factor therapy in idiopathic choroidal neovascularization

Evaluation of efficacy and recurrence for anti-vascular endothelial growth factor therapy in idiopathic choroidal neovascularization

Efficacy and safety of intravitreal injections of conbercept for the treatment of idiopathic choroidal neovascularization

Evaluation of efficacy and recurrence for anti-vascular endothelial growth factor therapy in idiopathic choroidal neovascularization

Contact Info

Product

Resources

About